Evidence map›Paper›PMID 41233467›Full record

ArticleScientific reports2025

Impact of COVID-19 restrictions on childhood allergic sensitization: a three-phase comparative study.

Wenxia Shao, Qingyi Shao

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wenxia ShaoDepartment of Laboratory Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Qingyi ShaoDepartment of Laboratory Medicine, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, 310052, Zhejiang, China. shaoqingyieve@163.com.

Funding

Zhejiang Provincial Natural Science Foundation of Chinaunder No. LKLY25H200004
6 · The paper itself

Abstract

This study aimed to investigate the influence of COVID-19 restrictions on the prevalence of allergen sensitivity in children. This study included patients who underwent allergen testing at our hospital before deregulation, after deregulation, and during the corresponding period in 2021. Changes in allergen-specific IgE (sIgE) positivity, IgE levels, and polysensitization were analyzed to to evaluate the impact of lifting COVID-19 restrictions on allergic diseases. Compared with those in the prederegulation period and the same period in 2021, the number of children with allergies visiting the hospital decreased following deregulation. The rate of allergen positivity was lower after deregulation than before but higher than that during the same period in 2021. After deregulation, allergen sIgE levels were lower than those before deregulation but higher than those in the same period in 2021. The correlation between milk and beef sensitivity was weaker after deregulation than before but stronger than that in 2021 (R values: 0.814, 0.854, and 0.104, respectively). During the period of COVID-19 restrictions, lower levels of allergic disease activity were observed compared to the pre-deregulation period. However, following the deregulation and the subsequent surge in COVID-19 infections, levels of allergic disease activity appeared to increase relative to the same observation period in 2021.

Indexed as

COVID-19HypersensitivityAdolescentAllergensChildChild, PreschoolFemaleFood HypersensitivityHumansImmunoglobulin EMalePrevalenceSARS-CoV-2AllergensImmunoglobulin EAllergensCOVID-19Nonpharmaceutical interactionssIgE

Identifiers

PMID41233467
PMCPMC12615688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.